Mutant p53 upregulates Nrf2 (nuclear factor erythroid 2 –related factor 2, a transcription factor coding for detoxification enzymes and conferring resistance to anticancer drugs) in non-small cell lung cancer by increased binding to the Nrf2 promoter supported by an activation of the NF-κB signaling pathway leading to additional enhancement of Nrf2 expression. Furthermore, loss of DNA mismatch repair favors cisplatin resistance in p53 mutant colon carcinoma cells. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.